Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs.

Casarin J, Song C, Multinu F, Cappuccio S, Liu E, Butler KA, Glaser GE, Cliby WA, Langstraat CL, Ghezzi F, Fu AZ, Mariani A.

Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31667-1. doi: 10.1016/j.ygyno.2019.11.016. [Epub ahead of print]

PMID:
31780236
2.

Psychosocial mechanisms of a behavioral treatment for urinary incontinence of prostate cancer survivors.

Zhang AY, Burant C, Fu AZ, Strauss G, Bodner DR, Ponsky L.

J Psychosoc Oncol. 2019 Nov 24:1-18. doi: 10.1080/07347332.2019.1678547. [Epub ahead of print]

PMID:
31762400
3.

Mood outcomes of a behavioral treatment for urinary incontinence in prostate cancer survivors.

Zhang AY, Ganocy S, Fu AZ, Kresevic D, Ponsky L, Strauss G, Bodner DR, Zhu H.

Support Care Cancer. 2019 Dec;27(12):4461-4467. doi: 10.1007/s00520-019-04745-w. Epub 2019 Mar 22.

PMID:
30903368
4.

Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China.

Liang Z, Zhang T, Lin T, Liu L, Wang B, Fu AZ, Wang X, Xu X, Luo N, Jiang J.

Qual Life Res. 2019 Aug;28(8):2069-2080. doi: 10.1007/s11136-019-02139-3. Epub 2019 Mar 4.

PMID:
30830645
5.

Costs associated with adverse events for systemic therapies in metastatic melanoma.

Fu AZ, Li Z, Tang J, Mahmood S, Whisman T, Qiu Y.

J Comp Eff Res. 2018 Sep;7(9):867-879. doi: 10.2217/cer-2018-0022. Epub 2018 Sep 7.

PMID:
30192155
6.

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.

7.

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group.

Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338. No abstract available.

PMID:
29784708
8.

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.

Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Diabetes Obes Metab. 2018 Aug;20(8):1983-1987. doi: 10.1111/dom.13299. Epub 2018 Apr 17.

9.

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11.

10.

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847. No abstract available.

PMID:
29483180
11.

Movement to outpatient hysterectomy for benign indications in the United States, 2008-2014.

Moawad G, Liu E, Song C, Fu AZ.

PLoS One. 2017 Nov 30;12(11):e0188812. doi: 10.1371/journal.pone.0188812. eCollection 2017.

12.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*.

Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.

13.

Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control.

Fu AZ, Sheehan JJ.

Curr Med Res Opin. 2017 May;33(5):853-858. doi: 10.1080/03007995.2017.1292231. Epub 2017 Mar 9.

PMID:
28166431
14.

Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.

Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL.

J Urol. 2017 Jun;197(6):1448-1454. doi: 10.1016/j.juro.2016.12.086. Epub 2016 Dec 19.

15.

Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.

Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL.

J Urol. 2017 May;197(5):1251-1257. doi: 10.1016/j.juro.2016.12.022. Epub 2016 Dec 16.

16.

Is a behavioral treatment for urinary incontinence beneficial to prostate cancer survivors as a follow-up care?

Zhang AY, Fu AZ, Moore S, Zhu H, Strauss G, Kresevic D, Klein E, Ponsky L, Bodner DR.

J Cancer Surviv. 2017 Feb;11(1):24-31. doi: 10.1007/s11764-016-0557-0. Epub 2016 Jun 24.

PMID:
27341843
17.

Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.

Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL.

World J Urol. 2016 Dec;34(12):1611-1619. Epub 2016 Apr 15.

18.

Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 diabetes mellitus.

Yu S, Fu AZ, Engel SS, Shankar RR, Radican L.

Curr Med Res Opin. 2016 Aug;32(8):1409-16. doi: 10.1080/03007995.2016.1176017. Epub 2016 May 5.

PMID:
27053004
19.

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.

Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J.

Diabetes Care. 2016 May;39(5):726-34. doi: 10.2337/dc15-0764. Epub 2016 Jan 6.

PMID:
26740636
20.

Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment.

Fu AZ, Graves KD, Jensen RE, Marshall JL, Formoso M, Potosky AL.

J Cancer Res Clin Oncol. 2016 Mar;142(3):699-706. doi: 10.1007/s00432-015-2073-4. Epub 2015 Nov 18.

Supplemental Content

Loading ...
Support Center